UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the 20 NYSE Stocks with the Lowest P/E Ratios.

UBS maintained its Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on September 24, 2025, but increased its price target from $23.00 to $26.00.

UBS raised its 2030 sales estimate from $6.3 billion to $6.6 billion, taking into account possible income from Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s new inhaler DARI, which is anticipated to launch in 2028, citing a stronger outlook for the company’s branded business. To boost sentiment around the stock, UBS also pointed out that Medicare’s pricing for Austedo will be clarified by November 30. It projects a 40% discount, which is less than the 60% some investors fear.

Globally, Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, markets, and distributes biopharmaceutical products and generic medications. Its product line includes tablets, capsules, injectables, inhalants, liquids, patches, ointments, creams, sterile goods, and combination therapies. It is one of the Stocks with Low PE Ratio.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.